Indivior (NASDAQ:INDV – Get Free Report) and Orion OYJ (OTCMKTS:ORINY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Profitability
This table compares Indivior and Orion OYJ’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Indivior | 26.65% | -283.11% | 36.85% |
| Orion OYJ | 28.52% | 50.37% | 30.65% |
Volatility and Risk
Indivior has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Orion OYJ has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500.
Earnings and Valuation
This table compares Indivior and Orion OYJ”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Indivior | $1.24 billion | 3.25 | $210.00 million | $2.79 | 12.24 |
| Orion OYJ | $2.14 billion | 6.16 | $566.04 million | $2.43 | 19.20 |
Orion OYJ has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Orion OYJ, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for Indivior and Orion OYJ, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indivior | 0 | 1 | 5 | 1 | 3.00 |
| Orion OYJ | 0 | 1 | 0 | 0 | 2.00 |
Indivior presently has a consensus target price of $45.17, suggesting a potential upside of 32.22%. Given Indivior’s stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Orion OYJ.
Summary
Indivior beats Orion OYJ on 9 of the 15 factors compared between the two stocks.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
About Orion OYJ
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
